Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
AMPH Stock Chart & Stats
$25.90
$1.14(3.23%)
At close: 4:00 PM EST
$25.90
$1.14(3.23%)
Day’s Range― - ―
52-Week Range$20.39 - $45.39
Previous CloseN/A
Volume255.86K
Average Volume (3M)434.87K
Market Cap
$1.18B
Enterprise Value$1.65B
Total Cash (Recent Filing)$278.64M
Total Debt (Recent Filing)$656.77M
Price to Earnings (P/E)11.5
Beta0.69
Next Earnings
Mar 04, 2026EPS Estimate
0.93Last Dividend Ex-Date
Jun 11, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding45,952,175
10 Day Avg. Volume326,497
30 Day Avg. Volume434,868
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)2.46
Price to Sales (P/S)2.46
P/FCF Ratio10.43
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue2.28
Enterprise Value/Gross Profit4.62
Enterprise Value/Ebitda7.45
Forecast
1Y Price Target
$29.67Price Target Upside14.56% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)3.36
Revenue Forecast (FY)$722.86M
Bulls Say, Bears Say
Bulls Say
EarningsAMPH's 3Q25 top-line of $191.8MM came in ahead of Street's $186.2MM, due to continued strength of Baqsimi and Primatene Mist.
Growth ProspectsThe company expects 3Q25 trends to continue over the remainder of 2025.
ValuationAmphastar Pharmaceuticals is considered undervalued based on current metrics and near-term growth catalysts.
Bears Say
Growth ExpectationsExpectations for a return to double-digit top-line growth in 2026 were somewhat moderated to high-single digit to low-double digits.
Amphastar Pharmaceuticals News
AMPH FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was $20.39 and its highest was $45.39 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Amphastar Pharmaceuticals’s market cap is $1.18B.
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 81 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.825 by $0.105.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals pays a Annually dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Amphastar Pharmaceuticals dividends here
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is 0.93.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 45,952,175 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of $0.93 in its last earnings report, beating expectations of $0.825. Following the earnings report the stock price went down -0.825%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Currently, no hedge funds are holding shares in AMPH
Amphastar Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.67 (14.56% Upside)
$29.67 (14.56% Upside)
Blogger Sentiment
Bullish
AMPH Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 42.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $555.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 3.3%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.55%
12-Months-Change
Fundamentals
Return on Equity
14.84%
Trailing 12-Months
Asset Growth
7.83%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of generic and specialty injectable pharmaceutical products. The company operates primarily in the injectable pharmaceuticals sector and is known for its expertise in producing high-quality formulations for a range of therapeutic areas, including anesthetics, anticoagulants, and antibiotics. Amphastar's core products include both generic drugs and proprietary formulations that cater to hospital and outpatient settings, aiming to improve patient care and reduce healthcare costs.
AMPH Company Deck
AMPH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Amphastar Pharmaceuticals showed resilience with strong sales growth in key products and strategic pipeline expansions, despite facing declines in specific product sales and increased competition. The litigation provision and reduced net income were notable challenges.View all AMPH earnings summariesAMPH Stock 12 Month Forecast
Average Price Target
$29.67
▲(14.56% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
25.36% Insiders
20.23% Mutual Funds
16.51% Other Institutional Investors
18.56% Public Companies and
Individual Investors